



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

13rd November 2025

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Thursday 13th November 2025, has approved the Standalone and Consolidated unaudited financial results, for the quarter and half year ended 30th September, 2025.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited Standalone financial results, for the quarter and half year ended 30th September 2025. (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II)
3. Statement of unaudited Consolidated financial results, for the quarter ended 30th September 2025. (Annexure-III)
4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-IV).

The Meeting Commenced on 04:00 p.m. and concluded on 06:00 p.m.

The above information will be made available on the Company's website
www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Amol Gupta
Chief Financial Officer



NATH SEEDS*

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 6 MONTHS ENDED 30/09/2025

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Audited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	3977.07	28017.18	3219.26	31994.25	27606.77	36230.81
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	3977.07	28017.18	3219.26	31994.25	27606.77	36230.81
II	Expenses						
	a) Production & Seed Conditioning Expenses	2054.56	10824.23	(52.27)	12878.79	6215.13	21754.92
	b) Purchase of Stock-in-Trade	27.70	435.33	375.07	463.03	643.81	1250.82
	c) Change in Inventories of Produced and Traded Goods	(794.98)	2379.62	923.83	1584.63	6679.21	(9665.64)
	d) Employee Benefit Expense	966.17	905.17	816.74	1871.34	1454.20	3030.88
	e) Depreciation & Amortisation Expenses	97.50	97.50	82.50	195.00	165.00	379.05
	f) Selling & Distribution Expenses	492.71	8669.91	314.59	9162.62	7317.06	11658.92
	g) Other Expenses	512.28	912.69	185.03	1424.97	935.25	2971.50
	Total Expenses	3365.95	24224.44	2645.49	27580.39	23409.65	31380.45
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	621.12	3792.74	573.76	4413.86	4197.12	4850.36
IV	Other Income	193.49	176.45	6.63	369.94	20.57	472.70
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	814.61	3969.19	580.39	4783.80	4217.69	5323.06
VI	Finance Cost	330.41	288.96	294.23	619.37	518.30	964.61
VII	Profit from Ordinary Activities after Finance cost (V-VI)	484.20	3680.23	286.17	4164.43	3699.39	4358.45
VIII	Exceptional Items Income/(Expenses)	0.00	206.34	0.00	206.34	0.00	54.03
IX	Profit from Ordinary Activities before Tax (VII-VIII)	484.20	3886.57	286.17	4370.77	3699.39	4412.48
X	Tax Expense						
	(a) Current Tax	64.11	65.97	13.73	130.08	38.26	203.70
	(b) Earlier Year Tax	0.00	0.00	(16.48)	0.00	(16.48)	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	420.09	3820.60	288.91	4240.69	3677.61	4214.01
XII	Extra Ordinary Items (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit for the period (XI-XII)	420.09	3820.60	288.91	4240.69	3677.61	4214.01
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.75)	(1.50)	(10.96)	(3.25)	(23.38)	(6.57)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(7.00)	(6.50)	0.00	(13.50)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(8.75)	(8.00)	(10.96)	(16.75)	(23.38)	(33.04)
XV	Total Comprehensive Income for the period (XIII + XIV)	411.34	3812.60	277.95	4223.94	3654.23	4180.97
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62966.30
XVIII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	2.16	20.06	1.46	22.23	19.23	22.00

NOTES:


- (1) The standalone financial results were reviewed by the Audit Committee in meeting held on 12 Nov 2025 and were thereafter approved by the Board of Directors at its meeting held on 13 Nov 2025
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) Investor complaints - Opening Balance - 0, Received and Solved - 0, Closing Balance - 0
- (4) The figures have been regrouped/rearranged where ever necessary.

Place : Chhatrapati Sambhajinagar

Date :13 Nov 2025

**GAUTAM HANDEWAT**
(Partner)

FOR NATH BIO-GENES (INDIA) LTD

SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajinagar - 431006 (MS)
www.nathbiogenes.com

UDIN:-25032742BMJJRY2876

Nath Bio-Genes (India) Limited		
Standalone Statement of Assets and Liabilities		
	Rs. In Lakhs	
Particulars	As at Year end 30.09.2025 (Unaudited)	As at Year end 31.03.2025 (Audited)
A ASSETS		
(1) Non Current Assets		
a) Property, Plant & Equipment	24,292.77	24,304.28
b) Capital Work in Progress	-	-
c) Other Intangible Assets	643.42	718.22
d) Intangible Assets under Development	-	-
e) Financial Assets		
(i) Investments	605.31	605.31
(ii) Loans	1,302.72	3,582.60
(iii) Non Current Financial Assets	-	-
f) Deferred Tax Assets (Net)	-	-
g) Other Non Current Assets	3,941.01	4,421.58
Total Non Current Assets	30,785.23	33,631.99
(2) Current Assets		
a) Inventories	30,548.16	33,070.82
b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	17,731.12	8,883.89
(iii) Loans	4,952.89	-
(iv) Cash and Cash Equivalents	35.01	8,763.30
(v) Bank balance other than (iii) above	-	-
(vi) Other Current Financial Assets	15,812.65	16,649.13
c) Current Tax Assets (Net)	365.19	365.19
d) Other Current Assets	316.50	322.33
Total Current Assets	69,761.52	68,054.66
TOTAL ASSETS	1,00,546.75	1,01,686.65
B EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
a) Share capital	1,900.40	1,900.40
b) Reserves and Surplus	66,826.92	62,966.31
c) Money received against share warrants	-	-
Sub-total - Shareholders' Fund	68,727.32	64,866.71
2. Share application money pending for allotment	-	-
3. Minotiries Interest	-	-
4. Non-current liabilities		
a) Long Term Borrowings	161.79	160.87
b) Deferred Tax Liabilities	-	-
c) Other Long Term Liabilities	-	-
d) Long Term Provisions	350.62	354.32
Sub-total - Non-current liabilities	512.41	515.19
5. Current Liabilities		
a) Short Term Borrowings	14,062.69	10,952.43
b) Trade Payables	6,932.37	7,874.33
c) Other Current Liabilities	10,093.49	17,354.29
d) Short Term Provisions	49.39	84.70
e) Current Tax Liabilities	169.08	39.00
	31,307.02	36,304.75
TOTAL - EQUITY AND LIABILITIES	1,00,546.75	1,01,686.65



FOR GAUTAM N ASSOCIATES

CHARTERED ACCOUNTANTS

GAUTAM NAWADAT

(Partner)

UDIN1-25032742BMJJRY287

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagiwal
MANAGING DIRECTOR

DIN 00119601



Place : Chhatrapati Sambhajnagar

Date : 13 Nov 2025

Nath Bio-Genes (India) Limited		
Standalone Statement of Cash Flow for the Half Year Ended 30.09.2025		
Particulars	Half Year ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Audited)
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax & Extra Ordinary items	4,370.77	4,412.49
Adjustment for :		
Depreciation	195.00	379.05
Provision for Compensated Absences & Gratuity	-22.26	50.63
Interest Paid / Financial Charges	619.37	964.61
Provisoin (Reversal of Provision) for Bad Debts	0.00	165.15
Provision for Doubtful Advances	0.00	-54.03
Profit on sale of Fixed Assets	0.00	0.00
Loss on Sale of Fixed Assets	-0.06	103.54
Expenses under Other Comprehensive Income	-16.75	-33.05
Interest Income	-335.16	-358.86
Operating Profit before working capital changes	4,810.91	5,629.53
Adjustment for :		
(Increase) / Decrease in Trade Receivables	-8,847.23	381.83
(Increase) / Decrease in Inventories	2,522.66	-10,163.78
(Increase) / Decrease in Loans & Advances and financial assets	-1,836.53	-2,793.60
(Increase) / Decrease in Other Current & Non Current Assets	486.40	-165.70
Increase / (Decrease) in Trade Payable	-941.96	3,667.11
Increase / (Decrease) in other current liabilities	-7,260.80	6,232.94
	-15,877.46	-2,841.20
Cash Generated from operation before Tax & Extra Ordinary item	-11,066.55	2,788.33
Income tax Paid	0.00	-108.39
Net Cash Flow from Operating Activities - (A)	-11,066.55	2,679.94
B) CASH FLOW FROM INVESTING ACTIVITIES		
Sale of fixed assets	0.60	10.54
Purchase of Fixed Assets (Tangible)	-109.23	-774.85
Purchase of Fixed Assets (In Tangible)	0.00	0.00
Payment for purchase for Investment	0.00	0.84
Interest Received	335.16	358.86
Other Non Current Assets		0.00
Purchase of Non Current Investment		
Net Cash Flow from Investing Activities - (B)	226.53	-404.61
C) CASH FLOW FROM FINANCING ACTIVITIES		
Interest Paid / Financial Charges	-619.37	-964.61
Dividend Paid	-380.08	-380.08
(Increase) / Decrease in Long Term Assets	0.00	0.00
Increase / (Decrease) in Long Term Borrowings	0.92	-121.82
Increase / (Decrease) in Long Term Provisions	0.00	0.00
Increase / (Decrease) in Short Term Borrowings	3,110.26	407.84
Increase / (Decrease) in Short Term Unsecured Loans	0.00	-3.49
Nett Cash Flow From Financing Activities - (C)	2,111.73	-1,062.16
Nett increase/Decrease in cash & cash equivalent (A+B+C)	-8,728.29	1,213.17
Opening Cash and Cash Equivalent	8,763.30	7,550.13
CLOSING CASH & CASH EQUIVALENT	35.01	8,763.30
	35.01	8,763.30



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

GAUTAM NANDAWAT

(Partner)

UDIN:- 25032742BMJJRY2876

Place : Chhatrapati Sambhajinagar
Date : 13 Nov 2025

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601





Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Nath Bio-Genes (India) Limited (CIN : L01110MH1993PLC072842)** for the quarter ended 30th September 2025 and year to date results for the period 1st April 2025 to 30th September 2025 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner
M No: 032742
UDIN: 25032742BMJJRY2876



Place: Chhatrapati Sambhajinagar
Date: 13th November 2025



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1003PLC072842)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND 6 MONTHS ENDED 30/09/2025

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Audited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	4384.96	28370.01	3219.26	32754.97	27606.77	36490.82
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	4384.96	28370.01	3219.26	32754.97	27606.77	36490.82
II	Expenses						
	a) Production & Seed Conditioning Expenses	2179.55	10885.18	68.51	13064.73	6707.33	22553.84
	b) Purchase of Stock-in-Trade	27.70	435.33	374.98	463.03	657.13	1273.48
	c) Change in Inventories of Produced and Traded Goods	(496.70)	2661.88	803.15	2165.19	6173.69	(10272.54)
	d) Employee Benefit Expense	1038.77	959.27	893.52	1998.04	1567.43	3250.38
	e) Depreciation & Amortisation Expenses	98.72	97.50	82.50	196.22	165.00	381.61
	f) Selling & Distribution Expenses	492.71	8669.91	314.59	9162.62	7317.06	11697.17
	g) Other Expenses	532.55	930.05	283.21	1462.60	1049.27	3008.66
	Total Expenses	3873.31	24639.12	2820.45	28512.43	23636.90	31892.60
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	511.65	3730.89	398.80	4242.55	3969.87	4598.22
IV	Other Income	193.49	176.45	7.55	369.94	20.57	454.58
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	705.15	3907.34	406.35	4612.49	3990.44	5052.80
VI	Finance Cost	365.71	319.61	297.77	685.31	521.84	1048.38
VII	Profit from Ordinary Activities after Finance cost (V-VI)	339.44	3587.74	108.59	3927.17	3468.60	4004.42
VIII	Exceptional Items Income/(Expenses)	206.34	0.00	0.00	206.34	0.00	0.00
IX	Profit from Ordinary Activities before Tax (VII-VIII)	545.78	3587.74	108.59	4133.51	3468.60	4004.42
X	Tax Expense						
	(a) Current Tax	64.11	65.97	13.73	130.08	38.26	203.70
	(b) Earlier Year Tax	0.00	0.00	(16.48)	0.00	(16.48)	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	481.67	3521.77	111.33	4003.43	3446.82	3805.95
XII	Extra Ordinary Items (Net of Tax)	(206.34)	206.34	0.00	0.00	0.00	54.03
XIII	Net Profit for the period (XI-XII)	275.33	3728.11	111.33	4003.43	3446.82	3859.98
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.75)	(1.50)	(10.96)	(3.25)	(23.38)	(6.58)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(7.00)	(6.50)	0.00	(13.50)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(8.75)	(8.00)	(10.96)	(16.75)	(23.38)	(33.05)
XV	Total Comprehensive Income for the period (VII + VIII)	266.58	3720.11	100.37	3986.68	3423.44	3826.93
XVI	Share in Profit / (Loss) of minority share holder	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Profit related to Holding Company	266.58	3720.11	100.37	3986.68	3423.44	3826.93
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62538.32
XVI	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	1.40	19.58	0.53	20.98	18.01	20.14


NOTES:

- The standalone financial results were reviewed by the Audit Committee in meeting held on 12 Nov 2025 and were thereafter approved by the Board of Directors at its meeting held on 13 Nov 2025
- The company is dealing in one major product segment, i.e. Seed Cultivation.
- The results have been consolidated with Nath Bio-Genes CA, Uzbekistan, where in the company is holding 90% of equity.
- Investor complaints - Opening Balance - 0, Received and Solved - 0, Closing Balance - 0
- The figures have been regrouped/rearranged where ever necessary.

Place : Chhatrapati Sambhajinagar
Date : 13 Nov 2025

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
Gautam
GAUTAM NANDAWAT
(Partner)

FOR NATH BIO-GENES (INDIA) LTD
Satish
SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601



Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajinagar - 431005 (MS)
www.nathbiogenes.com

UDIN: 25092942BMJJR25707

Nath Bio-Genes (India) Limited
(CIN L01110MH1993PLC072842)
Consolidated Statement of Assets and Liabilities

Rs. In Lakhs

Particulars	As at 30.09.2025 (Unaudited)	As at 31.03.2025 (Audited)
A ASSETS		
(1) Non Current Assets		
a) Property, Plant & Equipment	24,308.23	24,319.38
b) Capital Work in Progress	-	-
c) Other Intangible Assets	643.42	718.22
d) Intangible Assets under Development	-	-
e) Financial Assets	-	-
(i) Investments	583.09	578.18
(ii) Non Current Financial Assets	1,302.72	3,582.60
(iii) Others	-	-
f) Deferred Tax Assets (Net)	-	-
g) Other Non Current Assets	3,941.01	4,421.58
Total Non Current Assets	30,778.47	33,619.96
(2) Current Assets		
a) Inventories	30,796.43	33,801.59
b) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Receivables	17,935.28	8,890.15
(iii) Loans	4,952.89	-
(iv) Cash and Cash Equivalents	74.24	8,889.92
(v) Bank balance other than (iii) above	-	-
(vi) Other Current Financial Assets	15,812.65	16,649.13
c) Current Tax Assets (Net)	751.07	365.19
d) Other Current Assets	316.50	404.80
Total Current Assets	70,639.06	69,000.78
TOTAL ASSETS	1,01,417.53	1,02,620.74
B EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
a) Share capital	1,900.40	1,900.40
b) Reserves and Surplus	66,084.94	62,538.31
c) Money received against share warrants	-	-
Sub-total - Shareholders' Fund	67,985.34	64,438.71
2. Share application money pending for allotment	-	-
3. Minotiries Interest	-	-
4. Non-current liabilities	-	-
a) Long Term Borrowings	1,420.19	1,297.62
b) Deferred Tax Liabilities	-	-
c) Other Long Term Liabilities	-	-
d) Long Term Provisions	350.62	354.33
Sub-total - Non-current liabilities	1,770.81	1,651.95
5. Current Liabilities		
a) Short Term Borrowings	14,062.69	10,952.44
b) Trade Payables	6,932.37	7,948.35
c) Other Current Liabilities	10,428.88	17,505.59
d) Short Term Provisions	68.36	84.70
e) Current Tax Liabilities	169.08	39.00
	31,661.38	36,530.08
TOTAL - EQUITY AND LIABILITIES	1,01,417.53	1,02,620.74

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

0.00 0.00
FOR NATH BIO-GENES (INDIA) LTD



GAUTAM NAWADAT

(Partner)

UDIN:-25032742BRIJR25707

Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601




Place: Chhatrapati Sambhajinagar
Date: 13 Nov 2025

Nath Bio-Genes (India) Limited		
(CIN L0110MH1093PLC)		
Consolidated Statement of Cash Flow for the Half Year Ended 30.09.2025		
Rs in Lakhs		
Particulars	Half Year ended 30.09.2025 (Unaudited)	Year ended 31.03.2025 (Audited)
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax & Extra Ordinary items	4,133.51	4,058.44
Adjustment for :		
Depreciation	196.22	381.61
Provision for Compensated Absences & Gratuity		50.63
Interest Paid / Financial Charges	685.31	1,048.38
Provisoin (Reversal of Provision) for Bad Debts		165.15
Provision for Doubtful Advances		-54.03
Profit on sale of Fixed Assets		0.00
Loss on Sale of Fixed Assets		103.54
Expenses under Other Comprehensive Income		-33.05
Interest Income		-358.86
Operating Profit before working capital changes	5,015.04	5,361.81
Adjustment for :		
(Increase) / Decrease in Trade Receivables	-9,045.13	375.55
(Increase) / Decrease in Inventories	3,005.17	-10,770.68
(Increase) / Decrease in Loans & Advances and financial assets	-2,222.41	-2,793.60
(Increase) / Decrease in Other Current & Non Current Assets	568.87	-247.02
Increase / (Decrease) in Trade Payable	-1,015.98	3,618.74
Increase / (Decrease) in other current liabilities	-7,173.90	6,321.74
	-15,883.39	-3,495.27
Cash Generated from operation before Tax & Extra Ordinary item	-10,868.35	1,866.54
Income tax Paid	0.00	-108.39
Net Cash Flow from Operating Activities - (A)	-10,868.35	1,758.15
B) CASH FLOW FROM INVESTING ACTIVITIES		
Sale of fixed assets	0.60	10.54
Purchase of Fixed Assets (Tangible)	-110.45	-792.04
Purchase of Fixed Assets (In Tangible)	0.00	26.43
Payment for purchase for Investment	0.00	0.00
Interest Received	0.00	358.86
Other Non Current Assets	0.00	0.00
Purchase of Non Current Investment	-4.91	0.00
Net Cash Flow from Investing Activities - (B)	-114.76	-396.21
C) CASH FLOW FROM FINANCING ACTIVITIES		
Interest Paid / Financial Charges	-685.31	-1,048.38
Dividend Paid	-380.08	-380.08
(Increase) / Decrease in Long Term Assets	0.00	0.00
Increase / (Decrease) in Long Term Borrowings	122.57	811.11
Increase / (Decrease) in Long Term Provisions	0.00	0.00
Increase / (Decrease) in Short Term Borrowings	3,110.25	407.83
Increase / (Decrease) in Short Term Unsecured Loans	0.00	-3.49
Nett Cash Flow From Financing Activities - (C)	2,167.43	-213.01
Nett increase/Decrease in cash & cash equivalent (A+B+C)	-8,815.68	1,148.93
Opening Cash and Cash Equivalent	8,889.92	7,740.99
CLOSING CASH & CASH EQUIVALENT	74.24	8,889.92
	74.24	8,889.92
	-0.00	0.00

FOR NATH BIO-GENES (INDIA) LTD

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
GAUTAM NAWAWAT
(Partner)
UDIN: 25032742BMJIR25707
Place : Ghhatrapati Sambhajinagar
Date : 13 Nov 2025

Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601





Independent Auditor's Review Report on consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Nath Bio-Genes (India) Limited** (CIN: L01110MH1993PLC072842) ("the Parent") and its joint venture company (the Parent and its joint venture company together referred to as "the Group"), and its share of the net loss of its joint venture company for the quarter ended 30th September 2025 and for the period from 1st April 2025 to 30th September 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

A Joint Venture Entity is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in its country. The Unaudited Financial Statements of Joint Venture entity have been considered as authenticated by its management for the purpose of consolidation. The Parent Company's management has converted these financial statements of such joint venture located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India (Ind AS).

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Nath Bio-Genes (Central Asia) LLC., Uzbekistan a joint venture company.



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Our conclusion is not modified in respect of this matter.

For Gautam N Associates
Chartered Accountants
FRN: 103117W



Gautam Nandawat
Partner
M No: 032742
UDIN: 25032742BMJJRZ5707



Place: Chhatrapati Sambhajinagar
Date: 13th November 2025